Functional and Structural Assessment of the Effect of Human Umbilical Cord Blood Mesenchymal Stem Cells in Doxorubicin‐Induced Cardiotoxicity

Allah, Somia H. Abd; Hussein, Samia; Hasan, Mai M.; Deraz, Raghda; Hussein, Wafaa F.; Sabik, Laila M. E.

doi:10.1002/jcb.26168

Cited by 13 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bone marrow, adipose tissue, and umbilical cord blood are the most common sites for MSC extraction. The most commonly used cells in the reviewed studies were BMMSCs (Chen et al, 2006; Garbade et al, 2009; Mohammadi Gorji et al, 2012; Yu et al, 2014; Ammar et al, 2015; Dias et al, 2015; Deng et al, 2017; Soliman et al, 2017; Zeng et al, 2017) and human umbilical cord blood (hUCB)-MSCs (Gopinath et al, 2010; Di et al, 2012; Abd Allah and Hussein, 2017; Mao et al, 2017; Mousa et al, 2018). Fewer studies used adipose-derived stem cells (ADSCs) (Oliveira et al, 2013; Pınarlı et al, 2013) and fetal-derived stem cells (Haydardedeoglu et al, 2018).…”

Section: Factors That Influence the Outcome Of Msc Therapy For Dox Camentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate

et al. 2019

View full text Add to dashboard Cite

Over the past decades, researchers have reported several mechanisms for doxorubicin (DOX)-induced cardiomyopathy, including oxidative stress, inflammation, and apoptosis. Another mechanism that has been suggested is that DOX interferes with the cell cycle and induces oxidative stress in C-kit+ cells (commonly known as cardiac progenitor cells), reducing their regenerative capacity. Cardiac regeneration through enhancing the regenerative capacity of these cells or administration of other stem cells types has been the axis of several studies over the past 20 years. Several experiments revealed that local or systemic injections with mesenchymal stem cells (MSCs) were associated with significantly improved cardiac function, ameliorated inflammatory response, and reduced myocardial fibrosis. They also showed that several factors can affect the outcome of MSC treatment for DOX cardiomyopathy, including the MSC type, dose, route, and timing of administration. However, there is growing evidence that the C-kit+ cells do not have a cardiac regenerative potential in the adult mammalian heart. Similarly, the protective mechanisms of MSCs against DOX-induced cardiomyopathy are not likely to include direct differentiation into cardiomyocytes and probably occur through paracrine secretion, antioxidant and anti-inflammatory effects. Better understanding of the involved mechanisms and the factors governing the outcomes of MSCs therapy are essential before moving to clinical application in patients with DOX-induced cardiomyopathy.

show abstract

Section: Factors That Influence the Outcome Of Msc Therapy For Dox Camentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Anthracycline‐induced cardiotoxicity is attributed mainly to free radical formation in the mitochondria resulting in apoptosis of cardiac cells; MSCs were able to improve histopathologic and functional features and result in improved cardiac function after doxorubicin treatment in animal models . Additionally, bmMSCs were shown to regenerate doxorubicin‐induced nephropathy by reducing glomerular inflammation and preserving podocyte viability .…”

Section: Effects Of Chemotherapeutic Anti‐cancer Agents On Mscsmentioning

confidence: 99%

The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity

Rühle

Huber

Saffrich

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Chemotherapeutic agents are part of the standard treatment algorithms for many malignancies; however, their application and dosage are limited by their toxic effects to normal tissues. Chemotherapy-induced toxicities can be long-lasting and may be incompletely reversible; therefore, causative therapies for chemotherapy-dependent side effects are needed, especially considering the increasing survival rates of treated cancer patients. Mesenchymal stem cells (MSCs) have been shown to exhibit regenerative abilities for various forms of tissue damage. Preclinical data suggest that MSCs may also help to alleviate tissue lesions caused by chemotherapeutic agents, mainly by establishing a protective microenvironment for functional cells. Due to the systemic administration of most anticancer agents, the effects of these drugs on the MSCs themselves are of crucial importance to use stem cell-based approaches for the treatment of chemotherapy-induced tissue toxicities. Here, we present a concise review of the published data regarding the influence of various classes of chemotherapeutic agents on the survival, stem cell characteristics and physiological functions of MSCs. Molecular mechanisms underlying the effects are outlined, and resulting challenges of MSC-based treatments for chemotherapy-induced tissue injuries are discussed.

show abstract

“…In order to track MSCs in vivo, cell labelling was applied in 13 out of the 27 included studies. Only one study stated that labelling did not affect cell viability and function [31,35,[38][39][40][41][43][44][45][46][47][48][49]. As the effect of labelling was not addressed in 12 out of 13 studies, the initiating analysis was performed on labelled and unlabeled cells separately.…”

Section: Cell Labellingmentioning

confidence: 99%

Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Non-ischemic dilated cardiomyopathy (NIDCM) constitutes one of the most common causes to non-ischemic heart failure. Despite treatment, the disease often progresses, causing severe morbidity and mortality, making novel treatment strategies necessary. Due to the regenerative actions of mesenchymal stem cells (MSCs), they have been proposed as a treatment for NIDCM. This systematic review aims to evaluate efficacy and mode of action (MoA) of MSC-based therapies in NIDCM. A systematic literature search was conducted in Medline (Pubmed) and Embase. A total of 27 studies were included (3 clinical trials and 24 preclinical studies). MSCs from different tissues and routes of delivery were reported, with bone marrow-derived MSCs and direct intramyocardial injections being the most frequent. All included clinical trials and 22 preclinical trials reported an improvement in cardiac function following MSC treatment. Furthermore, preclinical studies demonstrated alterations in tissue structure, gene, and protein expression patterns, primarily related to fibrosis and angiogenesis. Consequently, MSC treatment can improve cardiac function in NIDCM patients. The MoA underlying this effect involves anti-fibrosis, angiogenesis, immunomodulation, and anti-apoptosis, though these processes seem to be interdependent. These encouraging results calls for larger confirmatory clinical studies, as well as preclinical studies utilizing unbiased investigation of the potential MoA.

show abstract

Functional and Structural Assessment of the Effect of Human Umbilical Cord Blood Mesenchymal Stem Cells in Doxorubicin‐Induced Cardiotoxicity

Cited by 13 publications

References 51 publications

Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate

Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate

The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity

Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review

Contact Info

Product

Resources

About